FDA accepts supplemental Biologics License Application for Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma August 16, 2022August 16, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA Advisory Committee votes in favour of the…CHMP recommends EU approval of Roche’s Polivy…Roche’s Polivy combination approved by European…Roche presents new and updated data for Polivy in…Roche’s Polivy combination reduced the risk of…FDA grants priority review to Roche’s bispecific…
